SLC5A2 and diabetic kidney disease: Based on this, clinical application of novel hypoglycaemic drugs such as daglitazine, a sodium‐glucose cotransporter‐2 (SGLT2) inhibitor, can increase urinary glucose excretion, control blood sugar and reduce glomerular injury, thereby delaying the deterioration of renal function in DKD.